Manufactured in accredited laboratories using advanced peptide synthesis methods, each Semaglutide vial is independently batch-tested to verify identity, purity, and consistency
Best Practices to Reduce Risk of Aspiration During Sedation/Anaesthesia To decrease gastric volume prior to sedation, thereby reducing the risk of aspiration, patients taking GLP-1 agonists either require doses of their medication to be held or to fast for longer periods than the current nil per os (NPO) guidelines
& Picardo, M
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin